D. Pinnaduwage

发表

Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival

S. Bull, I. Andrulis, A. Mulligan, 2018, BMC Cancer.

Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer

S. Bull, I. Andrulis, A. Mulligan, 2015, Cancer Immunology Research.

Non-invasive optical spectroscopic monitoring of breast development during puberty

L. Lilge, E. John, I. Andrulis, 2017, Breast Cancer Research.

Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation

S. Bull, B. Dickson, J. Wunder, 2020, Oncoimmunology.

Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction1

S. Bull, A. Logan, R. Hegele, 2003, Transplantation.

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry

I. Andrulis, A. Mulligan, F. O'Malley, 2011, Breast Cancer Research and Treatment.

Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors

S. Bull, I. Andrulis, F. O'Malley, 2008, Breast Cancer Research and Treatment.

Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

S. Bull, I. Andrulis, A. Mulligan, 2015, BMC Cancer.

Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

S. Bull, S. Agarwal, I. Andrulis, 2015, BMC Cancer.

Mena , a quantitative method of metastasis assessment , as a prognostic marker for axillary node-negative breast cancer

S. Bull, S. Agarwal, I. Andrulis, 2015 .

Mena [ superscript calc ] , a quantitative method of metastasis assessment , as a prognostic marker for axillary node-negative breast cancer

S. Bull, S. Agarwal, I. Andrulis, 2015 .

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer

Anna Marie Mulligan, Shelley B. Bull, Sean E. Egan, 2008, Breast Cancer Research and Treatment.

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer

Jason I. Herschkowitz, R. Cardiff, M. Hallett, 2013, Proceedings of the National Academy of Sciences.

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

R. Cardiff, S. Bull, M. Hallett, 2009, Proceedings of the National Academy of Sciences.

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

S. Bull, I. Andrulis, M. Blackstein, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aberrant Hedgehog Signaling and Clinical Outcome in Osteosarcoma

J. Wunder, I. Andrulis, D. Pinnaduwage, 2014, Sarcoma.

A role for the TGFβ-Par6 polarity pathway in breast cancer progression

J. Moffat, J. Wrana, R. Bose, 2009, Proceedings of the National Academy of Sciences.

Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry

I. Andrulis, A. Mulligan, F. O'Malley, 2012, Clinical Cancer Research.

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer

S. Bull, I. Andrulis, A. Mulligan, 2013, Breast Cancer Research and Treatment.

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1‐associated breast cancer in the Ontario site of the Breast Cancer Family Registry

S. Bull, I. Andrulis, A. Mulligan, 2011, Cancer.

1 Validation of Intratumoral T-bet + Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer

S. Bull, I. Andrulis, A. Mulligan, 2015 .

Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers

I. Andrulis, A. Mulligan, F. O'Malley, 2013, Breast Cancer Research and Treatment.

Protein Kinase C Epsilon and Genetic Networks in Osteosarcoma Metastasis

D. Merico, J. Wunder, I. Andrulis, 2013, Cancers.

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer

S. Bull, I. Andrulis, H. Ozçelik, 2007, Breast Cancer Research and Treatment.

Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information

S. Bull, I. Andrulis, A. Mulligan, 2014, Modern Pathology.

Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort

S. Bull, I. Andrulis, A. Mulligan, 2008, Clinical Cancer Research.

The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors

Irene L Andrulis, I. Andrulis, L. Bosnoyan-Collins, 2007, BMC Cancer.

Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival

S. Bull, I. Andrulis, A. Mulligan, 2018, BMC Cancer.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors

L. Murphy, M. Sherman, D. Rimm, 2014, Breast Cancer Research and Treatment.

Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.

I. Andrulis, L. Bosnoyan-Collins, D. Pinnaduwage, 2007, Neoplasia.

Genome-wide linkage analysis of systolic blood pressure slope using the Genetic Analysis Workshop 13 data sets

J. Beyene, D. Pinnaduwage, Shafagh Fallah, 2003, BMC Genetics.

Genome-wide association analyses of North American Rheumatoid Arthritis Consortium and Framingham Heart Study data utilizing genome-wide linkage results

Yun Joo Yoo, Shelley B Bull, Daryl Waggott, 2009, BMC proceedings.

LAF‐4 is aberrantly expressed in human breast cancer

I. Andrulis, M. To, S. Done, 2005, International Journal of Cancer.

Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers

S. Bull, I. Andrulis, A. Mulligan, 2019, Applied immunohistochemistry & molecular morphology : AIMM.